Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Future of Lung Cancer Treatment Looks Bright With Emerging Technologies, Novel Discoveries

November 8th 2021

Mark G. Kris, MD, discusses recent progress in non–small cell lung cancer and small cell lung cancer, efforts being made to address unmet needs in these paradigms, and ongoing research that is generating excitement.

Clinical Management of NTRK+ Advanced NSCLC

November 8th 2021

Ben Levy, Mark Socinski, and Stephen Liu describe the current treatment options for patients with NTRK+ NSCLC. They also summarize recent clinical data for agents that target NTRK.

Examining New Approaches to Management of Immune-Related AEs in Lung Cancer

November 6th 2021

With the rise of immunotherapy, patients with lung cancer are experiencing improved outcomes that have allowed for prolonged survival, but it is important to ensure that the adverse effects associated with these novel agents are effectively managed so that their achieved efficacy does not come at the cost of quality of life.

Immunotherapy/Chemo Combos Remain Go-To Option in Growing Small Cell Lung Cancer Paradigm

November 6th 2021

Chemoimmunotherapy is the new frontline standard of care for patients with small cell lung cancer, and other novel agents, such as, bispecific T-cell engagers are in the pipeline and gaining momentum for those who experience disease progression.

Timing of Immunotherapy Stoppage in Lung Cancer Varies Depending on Progression, AEs, and Cure

November 6th 2021

Each situation for stopping immunotherapy in lung cancer has its own complex nuances to consider before the decision is made to cease treatment.

Dr. Brahmer on the Utility of Consolidative Immunotherapy Vs Targeted Therapy in NSCLC

November 6th 2021

Julie Renee Brahmer, MD, MSc, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell lung cancer.

Dr. Kris on Next Steps to Improve Outcomes in Lung Cancer

November 6th 2021

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the next steps to improve outcomes for patients with lung cancer.

Dr. Ivanick on Advances in Interventional Pulmonology

November 5th 2021

Nathaniel Ivanick, MD, FCCP, discusses advancements in interventional pulmonology.

Dr. Seetharamu on Utilizing a Patient-Centered Treatment Approach in Lung Cancer

November 5th 2021

Nagashree Seetharamu, MD, MBBS, discusses the importance of utilizing a patient-centered treatment approach in lung cancer.

Dr. Zauderer on Emerging Treatment Strategies in Mesothelioma

November 5th 2021

Marjorie G. Zauderer, MD, discusses emerging treatment strategies in mesothelioma.

Boost in Genomic Testing, Multidisciplinary Input Needed for Personalized Lung Cancer Care

November 5th 2021

Nagashree Seetharamu, MD, MBBS, discusses the importance of early and frequent genomic testing in patients with lung cancer, as well as remaining challenges faced in clinical practice and efforts being made to overcome them.

Research With Cellular Therapy Ramps Up in Mesothelioma

November 5th 2021

Marjorie G. Zauderer, MD, previews some of the new approaches in mesothelioma.

Recent Updates in EGFR-Mutant NSCLC Treatment Landscape

November 5th 2021

Experts in lung cancer provide insight on recent updates from the ESMO Congress 2021 for the treatment of EGFR-mutant NSCLC.

Sequencing Treatments in EGFR-Mutant NSCLC

November 5th 2021

Vamsidhar Velcheti, MD, and Stephen Liu, MD, discuss their treatment approaches for patients with EGFR-mutant NSCLC who progress on osimertinib.

TROPION-PanTumor01 Study Design and Primary Data Analysis

November 4th 2021

Drs Heist and Peters examine data from the lung cohort of TROPION-PanTumor01 study that focused on dopotomab deruxtecan (Dato-DXd) as an antibody-drug conjugate therapy option.

NSCLC: Standard Treatment Approaches for EGFR Exon 20 Insertion Mutations

November 4th 2021

Current standard-of-care approaches toward the management of patients with non–small cell lung cancer with EGFR exon 20 insertion mutations.

EGFR Exon 20 Insertion Mutations as a Therapeutic Target in NSCLC

November 4th 2021

In the setting of non–small cell lung cancer, experts consider the importance of EGFR exon 20 insertion mutations as a therapeutic target.

Association of Community Cancer Centers Announces Findings of National Initiative to Support Quality Care for Stage III and IV NSCLC

November 2nd 2021

The Association of Community Cancer Centers in collaboration with AstraZeneca, a global, science-led biopharmaceutical company, has announced the findings of a national quality care initiative for patients with stage III and stage IV non-small cell lung cancer.

Dr. Sabari on Selecting Between Available ALK inhibitors in ALK+ NSCLC

November 1st 2021

Joshua K. Sabari, MD, discusses selecting between available ALK inhibitors in ALK-positive non–small cell lung cancer.

Rapid Readouts: Larotrectinib Prior Therapy and Performance Status Outcomes in Patients With Non-CNS TRK Fusion Cancer

November 1st 2021

Alexander Drilon, MD, discusses prior therapy and performance status outcomes for larotrectinib in patients with non-CNS TRK fusion cancer that were presented at the European Society of Medical Oncology 2021 annual meeting.